Doctors from Leading Cancer Center Will Discuss Firsthand Experience with MRIdian's Adaptive and Soft-Tissue Tracking Capabilities
CLEVELAND - ViewRay™, a privately held medical device company, announced today that it will showcase its MRIdian™ (me-rid-i-an) system, the world's first and only MRI-guided radiation therapy system, at the 56(th) Annual Meeting of the American Society for Radiation Oncology (ASTRO) being held September 14-17, 2014 in San Francisco. With ViewRay's recent announcements of the world's first on-table adaptive radiation therapy treatment at Siteman Cancer Center and the first patient treated at the University of Wisconsin Carbone Center using soft-tissue tracking, a high level of interest is anticipated around MRI-guided radiation therapy at this year's meeting. A number of clinical presentations will be focused on experience with the MRIdian system in the ASTRO-sponsored Scientific Sessions and in the company's booth, including user experience with MRIdian's adaptive and soft-tissue tracking capabilities.
"Clinicians have been waiting for years for an integrated system that can provide continuous soft-tissue imaging during treatment so they can see the dose delivered and adapt to changes and movement in their patients' anatomy in real-time," said Chris A. Raanes, ViewRay president and CEO. "The fact that this dream is now a reality with the MRIdian system is a huge step forward for doctors and their patients. With some of the first users presenting on their experience at this year's meeting, we expect a great deal of discussion and interest in MRIdian."
Of the various presentations featuring the MRIdian system during ASTRO, one was awarded a "Best of ASTRO" designation by the organization and will be given on Tuesday, September 16 during the Physics Scientific Session on MRI Guided Radiation Therapy beginning at 4:45 p.m. PDT. The talk, titled "The Dawn of a New Era: First Ever MR-IGRT Treatments - Initial Experiences and Future Implications" will be given by Sasa Mutic, Ph.D., Director of Medical Physics at Washington University. For a list of other Scientific Session talks that will focus on the MRIdian system please visit: http://www.viewray.com/astro_2014.htm.
The company will be exhibiting at booth 416 where attendees can also hear about clinical experiences and patient workflow during presentations by a number of clinician users of the MRIdian system. Presentations will take place at various times from Sunday, September 14 through Tuesday, September 16, with a detailed schedule available here. Speakers include Rojano Kashani, Ph.D., medical physicist, and Jeffrey Olsen, M.D., treating physician of the first patient treated with on-table adaptive radiation therapy at the Siteman Cancer Center at Washington University in St. Louis. Both presenters will discuss their experience with MRI-guided radiation therapy and the clinical impact of adaptive therapy.
Additionally, visitors to the company's booth can receive a treatment planning demonstration and view plan comparisons to see the quality of MRIdian's soft-tissue imaging and understand the value it can provide in adaptive treatment planning.
ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The MRIdian system provides continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit http://www.viewray.com.
ViewRay and MRIdian are trademarks of ViewRay Incorporated.
ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.
Contact: Michael Saracen, Senior Director, Marketing, ViewRay Incorporated, Phone: +1 440-703-3210, ext. 200, Email: email@example.com
Web Site: http://www.viewray.com